Pharsight

Aczone generic

Aczone is an anti-acne medication owned by Almirall. This drug, containing dapsone, was first authorized for market use on the 24th of February, 2016.

When will Aczone generic be available?

The generic version of Aczone could become available after the 18th of November, 2033, when the last patent expires.

Aczone uses

Aczone is used for the topical treatment of acne vulgaris. Its active ingredient, dapsone, is effective in managing this skin condition.

Aczone patent expiration

Aczone holds three drug patents, with none expired yet. The expiration date for these patents is November 18th, 2033. To get more details on when the Aczone generic could potentially become available, refer to the patent details. Below are the details of the patents:

Litigations filed on Aczone

Aczone dosage

Want to ask something?